These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31552220)

  • 1. Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines.
    Pavlin M; Gelsomino L; Barone I; Spinello A; Catalano S; Andò S; Magistrato A
    Front Chem; 2019; 7():602. PubMed ID: 31552220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
    Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
    Elife; 2022 May; 11():. PubMed ID: 35575456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers.
    Pavlin M; Spinello A; Pennati M; Zaffaroni N; Gobbi S; Bisi A; Colombo G; Magistrato A
    Sci Rep; 2018 Jan; 8(1):649. PubMed ID: 29330437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
    Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S
    Young KS; Hancock GR; Fink E; Zigrossi A; Flowers B; Cooper DA; Nguyen VT; Martinez M; Mon KS; Bosland M; Zak D; Runde A; Sharifi MN; Kastrati I; Minh DDL; Kregel S; Fanning SW
    Res Sq; 2024 Jun; ():. PubMed ID: 38978585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S
    Young KS; Hancock GR; Fink E; Zigrossi A; Flowers B; Cooper DA; Nguyen VT; Martinez M; Mon KS; Bosland M; Zak D; Runde A; Sharifi MN; Kastrati I; Minh DDL; Kregel S; Fanning SW
    bioRxiv; 2024 Jun; ():. PubMed ID: 38854123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
    Fanning SW; Mayne CG; Dharmarajan V; Carlson KE; Martin TA; Novick SJ; Toy W; Green B; Panchamukhi S; Katzenellenbogen BS; Tajkhorshid E; Griffin PR; Shen Y; Chandarlapaty S; Katzenellenbogen JA; Greene GL
    Elife; 2016 Feb; 5():. PubMed ID: 26836308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
    Fanning SW; Jeselsohn R; Dharmarajan V; Mayne CG; Karimi M; Buchwalter G; Houtman R; Toy W; Fowler CE; Han R; Lainé M; Carlson KE; Martin TA; Nowak J; Nwachukwu JC; Hosfield DJ; Chandarlapaty S; Tajkhorshid E; Nettles KW; Griffin PR; Shen Y; Katzenellenbogen JA; Brown M; Greene GL
    Elife; 2018 Nov; 7():. PubMed ID: 30489256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short chain fatty acids exhibit selective estrogen receptor downregulator (SERD) activity in breast cancer.
    Schoeller A; Karki K; Jayaraman A; Chapkin RS; Safe S
    Am J Cancer Res; 2022; 12(7):3422-3436. PubMed ID: 35968335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cadmium activation of wild-type and constitutively active estrogen receptor alpha.
    Psaltis JB; Wang Q; Yan G; Gahtani R; Huang N; Haddad BR; Martin MB
    Front Endocrinol (Lausanne); 2024; 15():1380047. PubMed ID: 39184142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
    Busonero C; Leone S; Bartoloni S; Acconcia F
    Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
    Laws MJ; Ziegler Y; Shahoei SH; Dey P; Kim SH; Yasuda M; Park BH; Nettles KW; Katzenellenbogen JA; Nelson ER; Katzenellenbogen BS
    Breast Cancer Res Treat; 2020 Jun; 181(2):297-307. PubMed ID: 32277377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.
    Cipolletti M; Acconcia F
    Mol Cell Endocrinol; 2024 Apr; 584():112160. PubMed ID: 38266771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
    Caciolla J; Martini S; Spinello A; Pavlin M; Turrini E; Simonelli F; Belluti F; Rampa A; Bisi A; Fimognari C; Zaffaroni N; Gobbi S; Magistrato A
    Eur J Med Chem; 2021 Nov; 224():113733. PubMed ID: 34364162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines.
    Gelsomino L; Panza S; Giordano C; Barone I; Gu G; Spina E; Catalano S; Fuqua S; Andò S
    Cancer Lett; 2018 Aug; 428():12-20. PubMed ID: 29702197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants.
    Chigira T; Nagatoishi S; Tsumoto K
    Biochem Biophys Res Commun; 2015 Aug; 463(4):726-31. PubMed ID: 26049107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
    Busonero C; Leone S; Bianchi F; Acconcia F
    Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.
    Zhao Y; Laws MJ; Guillen VS; Ziegler Y; Min J; Sharma A; Kim SH; Chu D; Park BH; Oesterreich S; Mao C; Shapiro DJ; Nettles KW; Katzenellenbogen JA; Katzenellenbogen BS
    Cancer Res; 2017 Oct; 77(20):5602-5613. PubMed ID: 28904064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation.
    Huggins RJ; Greene GL
    NPJ Breast Cancer; 2023 Nov; 9(1):96. PubMed ID: 38036546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.